Anti-Aging Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Aging Population Expansion

The global population aged 65 and above grew from 732.9 million in 2020 to 854.6 million in 2025. That increase of 121.7 million, or 16.6%, enlarges the potential audience for products addressing age-related appearance concerns. For manufacturers of anti-wrinkle products, demographic expansion offers a source of potential demand beyond switching buyers between brands. For device suppliers, the relevant commercial question is how much additional treatment capacity providers would need if more older adults seek skin-tightening procedures. This makes aging a long-term demand driver whose commercial effect depends on converting a broader population into product users or treatment recipients.

Rising Demand For Minimally-Invasive Aesthetic Procedures

A growing skin-tightening service business can increase demand for the equipment used to deliver treatment, connecting patient activity with an aesthetic supplier's commercial opportunity. Based on its plastic-surgeon survey, the International Society of Aesthetic Plastic Surgery (ISAPS) estimated 1.53 million non-surgical skin-tightening procedures worldwide in 2025, up 23.3% from 2024.^[1] The Aesthetic Society describes radiofrequency, intense pulsed light or broad band light, and ultrasound among the equipment options surgeons select for non-surgical skin tightening. The availability of several modalities means the same treatment category can generate demand for different equipment, depending on the surgeon's selected approach. Procedure growth consequently expands the clinical workload open to device suppliers, and each modality's supplier competes for the share of that workload that surgeons assign to it.

Growing Male Grooming & Self-Care Spend

Male participation in targeted skincare creates an opening for anti-aging brands through specific product formats rather than an undifferentiated grooming proposition. Among German men aged 18-49, face-mask buyer reach rose from 8.5% in 2019 to 13.6% in 2025. In Germany, the share of men aged 18-49 buying serums at least once a year rose from 2.2% in 2019 to 6.1% in 2025.^[2] These categories include active-ingredient products often aimed at skin aging, hyperpigmentation, or vitamin needs. Greater participation in these formats creates a potential audience for age-related formulations within an established skincare purchase.

AI-Driven Personalized Skin-Care Algorithms

Personalized skin diagnostics can connect a consumer's specific concern with a product recommendation, creating a more direct route from assessment to potential demand. L'Oréal Paris offers Beauty Genius, an AI assistant with selfie-based personalized skin diagnostics and product recommendations, on its US website and WhatsApp. The assistant draws its recommendations from a curated base of more than 750 L'Oréal Paris products. An assessed skin concern can therefore become a recommendation from the brand's own range, giving an undecided shopper a direct path to a specific purchase.

Stringent Multi-Region Cosmetic Regulations

Access to European Union cosmetic buyers depends on meeting legal entry conditions before a supplier can monetize demand for its anti-aging range. EU cosmetics rules require a product safety report before market placement and an EU-designated responsible person for products placed on the EU market.^[3] These obligations make both product documentation and local legal accountability part of the commercial launch decision for manufacturers entering the bloc. In its 2025 staff review, the European Commission reported cosmetics-industry stakeholder concerns that accelerating CLP classifications require reformulations and can lead to discontinuing products that cannot be reformulated or would suffer significant performance compromises. Reformulation therefore adds a potential post-launch burden to pre-market compliance, with the risk of losing a product's commercial life when acceptable performance cannot be preserved.

Adverse Effects & Efficacy Skepticism

Uncertainty about safety and achievable outcomes can hold back cosmetic treatment decisions before an interested consumer becomes a patient. In a 2025 nationwide US survey of more than 3,500 consumers by the American Society for Dermatologic Surgery (ASDS), 16% cited side effects and safety among reasons for waiting to proceed with a cosmetic procedure. In the same survey, 11% were concerned they might not obtain their desired results. Waiting to proceed can defer treatment starts, which postpones the injectable and equipment demand that depends on those procedures.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Anti-Aging Market Segment Analysis

Anti-wrinkle products accounted for a 29.84% share of the anti-aging market size in 2026. Shiseido's ELIXIR main wrinkle-cream series ranked first by estimated series sales value in Japan's wrinkle-improving medicated skincare cosmetics category for 8 consecutive years from May 2017 through April 2025, according to INTAGE SRI+ data. That duration demonstrates a sustained commercial position for a product franchise centered on a specific skin concern. A rival topical brand in Japan's wrinkle-care category must therefore overcome a franchise that held first place by estimated series sales value for 8 consecutive years.

Dermal fillers and injectables are the fastest-growing segment, with a forecast CAGR of 9.55% over 2027-2032. In its preliminary 2025 results, Hugel reported global dermal-filler net sales of KRW 129.7 billion (USD 91.2 million), demonstrating an established commercial base for the category. On August 11, 2026, Galderma received EU Medical Device Regulation approval for Restylane Shaype, a hyaluronic acid injectable for temporary chin augmentation. Sunscreen and UV absorbers address a preventive opportunity, with the American Academy of Dermatology's 2026 survey finding 21% of Americans unaware sunscreen helps prevent premature aging. Injectable expansion can thus come from authorizing additional treatment uses, while sunscreen suppliers face the separate task of explaining prevention.

Radio-frequency devices represented a 26.92% anti-aging market share in 2026. The largest segment includes Thermage, a monopolar radiofrequency skin-tightening system supplied by Solta Medical, Bausch Health's aesthetics business. Solta Medical reported that cumulative Thermage-family tip sales exceeded 5 million worldwide by September 2025. New radiofrequency entrants therefore compete against a tightening platform with a substantial cumulative tip-sales base.

Laser and light-based devices are the fastest-growing segment, with a forecast CAGR of 10.05% over 2027-2032. El.En. Group's broader aesthetic-systems revenue rose 11.02% year over year in the first half of 2026, including anti-aging lasers and microwave-based Onda Pro, while hair-removal sales declined. Bausch Health and Solta Medical announced the Canadian launch of Clear + Brilliant Touch on February 23, 2026, following Health Canada approval on May 20, 2025. These routes give laser suppliers a choice between expanding the applications served within an aesthetic portfolio and extending an authorized system into another national provider market.

Anti-wrinkle treatment was the largest segment, accounting for 35.39% of market revenue in 2026. ISAPS estimated that plastic surgeons performed 7.33 million aesthetic botulinum-toxin procedures worldwide in 2025. Botulinum toxin accounted for 42.3% of the non-surgical procedures ISAPS surveyed, the largest non-surgical category in the survey. For suppliers of injectable wrinkle treatments, the route to product revenue therefore runs through providers carrying this clinical workload.

Cellulite reduction is the fastest-growing segment, with a forecast CAGR of 12.4% over 2027-2032. In December 2025, Galderma received EU Medical Device Regulation certification for Sculptra body indications, including the gluteal area and posterior thighs, where it can improve cellulite appearance. The certification adds 4 body areas, the gluteal area, posterior thighs, décolletage and upper arms, to Sculptra's facial use. Galderma describes treatment goals in these areas ranging from skin quality, including cellulite appearance, to firmness, lift, projection and contouring. Cellulite appearance is one treatment goal within this broader certified scope, so demand tied to cellulite reduction depends on practitioners selecting that goal for patients.

Hypermarkets and supermarkets were the largest segment, accounting for 40.65% of market revenue in 2026. Carrefour reported 320 hypermarkets and 1,174 supermarkets under its banners in France at September 30, 2026. For skincare suppliers, a retailer with an established network offers potential reach across many locations. Supermarkets outnumber hypermarkets by more than 3 to 1 in Carrefour's French network, so a supplier listed only in hypermarkets reaches far fewer potential locations than one listed in both formats.

E-commerce is the fastest-growing segment, with a forecast CAGR of 14.6% over 2027-2032. L'Oréal reported double-digit like-for-like growth in its global beauty e-commerce sales in the first half of 2026, nearly twice as fast as the beauty market. Its measure includes brand websites, sales to online pure players, and the online portion of sales to traditional retailers. Because the measure counts the online portion of sales to traditional retailers, a brand sold mainly through stores can still participate in the channel through its retail partners' websites.

Hospitals and surgery centers were the largest segment, accounting for 40.99% of market revenue in 2026. In ISAPS's plastic-surgeon survey, hospitals hosted 48.7% of worldwide cosmetic procedures in 2025. Free-standing surgery centers hosted 20.2%, compared with 29.8% in office facilities. Together, hospitals and surgery centers hosted most of the cosmetic procedures in the survey. Suppliers that sell into institutional buyers therefore address the settings where more than two thirds of the surveyed procedures took place.

At-home use is the fastest-growing segment, with a forecast CAGR of 9.35% over 2027-2032. The Beauty Tech Group plc reported that CurrentBody Skin revenue grew 44.9% in the first half of FY2026, ended June 30, with growth from its LED range across anti-aging and hair regrowth. A device range spanning more than one use gives a home-beauty supplier several application-specific offerings to develop within the same consumer brand. Dermatology clinics have a distinct patient-facing role, with ASDS's 2025 US survey of more than 3,500 consumers finding dermatologists were the physician of choice in 12 cosmetic-procedure categories. Home-device suppliers can pursue direct product demand while specialist practices compete through the physician relationship, creating different ways to capture spending around a cosmetic concern.

Geography Analysis

North America Anti-Aging Market

North America held 36.71% of the anti-aging market size in 2026, making it the largest region. In 2025, AbbVie reported US revenue of USD 1.5 billion for Botox Cosmetic and USD 385 million for the Juvederm Collection. These product-level revenues demonstrate a substantial US commercial base for aesthetic injectables, giving the region's lead a concrete supplier-sales context. Botox Cosmetic revenue declined 10.5% from 2024, while Juvederm Collection revenue declined 18% over the same period. The scale of these US injectable franchises provides a commercial foundation for North America's lead even as their sales decline.

Asia-Pacific Anti-Aging Market

Asia-Pacific is the fastest-growing region, with a forecast CAGR of 9.6% over 2027-2032. Sisram Medical reported Asia-Pacific group revenue of USD 78.4 million in the first half of 2026, up 19.1% year over year. Sisram's broader portfolio spans energy-based medical aesthetic devices, injectables and complementary solutions, so its Asia-Pacific revenue is tied to both device placements and injectable sales.

In Europe, skin care was the largest cosmetics and personal-care product category by retail sales value in 2025. Within South America, Brazil recorded 2.36 million surgical aesthetic procedures in 2025, the most surgical procedures of any country in ISAPS's plastic-surgeon survey. In the Middle East and Africa, ISAPS's 2025 survey identified Tunisia among the countries with the highest proportions of foreign patients for aesthetic procedures. European topical suppliers can address an established consumer skincare category, while Brazil's surgical activity makes professional providers relevant customers for treatment-related supply. The foreign-patient mix in Tunisia also makes local resident counts an incomplete guide to the patient base served by its aesthetic providers.

Regulatory Framework and Outlook

Selected jurisdictions are compared from the perspective of anti-aging cosmetic manufacturers, focusing on product entry, documentation, and claims compliance. The commercial effect depends on whether work is required before entry, recurs during sales, or accompanies a future regulatory transition. Pre-market documentation in Germany and registration of covered cosmetics in Argentina sit alongside applicable US listing updates and China's registrant and filing-entity quality-management duties.

The US rating reflects recurring compliance work and possible additional labeling duties for affected products under a planned proposed rule with a November 2026 agenda target. Germany's paperwork burden is balanced by a June 2026 provisional simplification agreement awaiting formal adoption, while China's announced filing optimization offers easing alongside continuing safety duties and the January 1, 2028 standard transition. South Africa's 2026 claim-substantiation test supports continuity in advertising compliance. Argentina balances simpler establishment entry with retained product duties, while regional commencement of its May 2026 substances rule depends on notification that all member states have incorporated it.

Value Chain Stages

The value chain compares how ingredient supply, distribution, formulation, and finished-product delivery contribute different capabilities to commercial anti-aging offerings. In 2025, L'Oréal filed 725 patents and had 22 cosmetic research centers and 13 assessment centers across its cosmetics business. On March 12, 2026, Ashland announced that IMCD US, LLC would become its exclusive US distributor for personal-care and home-care ingredients effective April 1, including portfolios for skin, hair, oral, and home care. These distinct capabilities place commercial value both in developing assessed formulations and in connecting ingredient suppliers with the businesses that formulate finished products.

Integrated cosmetic producers can retain value from research through manufacturing, while specialist device suppliers capture revenue through a different technical offering. L'Oréal's 37 worldwide factories in 2025 illustrate its broader cosmetics manufacturing scale, complementing its research infrastructure. Future structural advantage can therefore come from connecting assessment and production within a product business, while maintaining the specialist capabilities required to supply aesthetic equipment.

Key Opportunities for Market Participants

The opportunities compare distinct routes for translating longevity research into future cosmetic skincare products. On August 11, 2026, L'Oréal Groupe and NUS Medicine announced a multi-year research partnership and joint laboratory in Singapore to study skin, scalp, and hair in healthy aging. Commercial applications depend on the research findings, making formulation development the relevant opening rather than immediate consumer adoption. For skincare producers, the decision is which research pathway can support a specific cosmetic use and a product that can be manufactured at commercial scale.

The central opening is a cosmetic product with a defined benefit that can carry longevity research into a repeatable formulation. A producer therefore needs research partners that can test whether the proposed biological mechanism produces a benefit in a finished cosmetic formulation. Those results can determine which candidate receives scale-up investment, allowing capacity commitments to follow demonstrated product performance.